[The treatment of urogenital tuberculosis with current drugs].
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003523:Cycloserine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000517:prevention & control; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate; D007612:Kanamycin / Q000627:therapeutic use; D010670:Phenylthiourea / Q000031:analogs & derivatives / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D014376:Tuberculosis / Q000453:epidemiology; D014401:Tuberculosis, Urogenital / Q000188:drug therapy*; D014756:Viomycin / Q000627:therapeutic use
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007612:Kanamycin; D010670:Phenylthiourea; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D012293:Rifampin; D014756:Viomycin
Die Behandlung der Urogenitaltuberkulose mit neueren Medikamenten.